BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Talks.cam//talks.cam.ac.uk//
X-WR-CALNAME:Talks.cam
BEGIN:VEVENT
SUMMARY:Off-the-shelf models of chromosomal translocations and using antib
 ody fragments as cancer drug surrogates - Terry Rabbitts\, Leeds Institute
  of Molecular Medicine
DTSTART:20110131T161500Z
DTEND:20110131T180000Z
UID:TALK29228@talks.cam.ac.uk
CONTACT:Scientific Meetings Co-ordinator
DESCRIPTION:Chromosomal translocations are primary somatic events found in
  all forms of cancer\, ranging from leukaemia/lymphomas\, sarcomas and epi
 thelial tumours. This kind of genomic disturbance has major consequences i
 n cancer initiating cells\, often through the creation of a gene fusion or
  by altered gene expression through abnormal transcriptional contexts. The
  protein products of chromosomal translocations are intracellular and ofte
 n function through protein-protein interaction in the cytoplasm or nucleus
  of cancer cells. We are translating these findings into therapeutic  appl
 ications by developing pre-clinical models of human cancer and targeting c
 ancer-associated protein-protein interactions for drug target validation. 
 I will describe our “fast throughput” mouse cancer modeling enabling r
 ecapitulation of corresponding human cancers for pre-clinical studies. We 
 are using such models to evaluate the efficacy of antibody fragments as dr
 ug surrogates. Preliminary data will be presented about the use of structu
 re/function-based methods to develop chemical compounds that mimic the cri
 tical binding residues of antibody fragments (small molecule emulators of 
 antibody binding sites) as leads for anti-cancer drug development.
LOCATION:Max Perutz Lecture Theatre\, Medical Research Council (MRC) (MRC 
 Laboratory of Molecular Biol
END:VEVENT
END:VCALENDAR